Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ArriVent BioPharma, Inc. Common Stock(AVBP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AVBP
09/15/2026: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
ArriVent BioPharma is a clinical-stage company focused on developing oncology therapies, most notably its lead candidate, furmonertinib, for lung cancer. The company utilizes a lean licensing model to identify and advance drug assets, aiming to bridge the gap between innovation and market access. Its primary strength lies in its experienced leadership and a focused strategy on late-stage clinical trials. However, investors face significant risks, including pipeline concentration, lack of current revenue, and intense competition from larger pharmaceutical entities. The stock is best suited for growth-oriented investors with a high risk tolerance who are closely monitoring upcoming clinical trial results and regulatory decisions.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success but carries substantial binary risk. |
| Momentum investor | Weak fit | Momentum is highly conditional on clinical data readouts and positive market sentiment, which is volatile. |
| Value investor | Weak fit | As a pre-revenue clinical-stage company, there is no traditional earnings-based valuation foundation. |
| Dividend investor | Weak fit | ArriVent does not pay dividends and focuses all capital on pipeline development. |
| Low-risk investor | Weak fit | The biotech sector, particularly pre-revenue clinical firms, is subject to high price volatility and capital risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant share price swings. |
| Valuation risk | High | Without revenue, valuations are speculative and tied to clinical trial probabilities. |
| Competition risk (EGFR inhibitors) | Medium / high | ArriVent competes against well-funded incumbents with strong market presence. |
| Business quality | Medium | The company is a focused developer without a diversified commercial product base. |
| Dividend income | Low / none | No income potential for shareholders. |
| Execution risk | Medium / high | Regulatory and clinical execution are essential for future value creation. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -32.93% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio - | 1Y Target Price 44.7 |
Price to earnings Ratio - | 1Y Target Price 44.7 | ||
Volume (30-day avg) 441.9K shares | Beta 1.36 | 52 Weeks Range 17.00 - 35.83 | Updated Date 09/15/2026 |
52 Weeks Range 17.00 - 35.83 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Therapeutics | Clinical-stage EGFR inhibitors aimed at treating lung cancer. | The company is currently spending money to develop drugs and has not yet sold any products. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.06B | Price to Sales(TTM) - |
Enterprise Value 1.06B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 49.31M | Shares Floating 32.11M |
Shares Outstanding 49.31M | Shares Floating 32.11M | ||
Percent Insiders 1.54 | Percent Institutions 98.67 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquarters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | Website https://arrivent.com |
Full time employees 77 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.